Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better healthCARDIOVASCULAR PROTECTIONBEYOND BLOOD PRESSURE CONTROL[ brain]Ultimate goal – prevention of stroke,heart attack, kidney failure[ kidney ]CONTROLLING HYPERTENSION ANDCARDIOVASCULAR PROTECTION[ heart ]Controlling blood pressure is one of the most important factors toreduce cardiovascular events. The primary cardiovascular concern ofphysicians is treating high blood pressure. The goal is also to preventthe life-threatening events of stroke, heart attack or kidney failurethat can result from complications of high blood pressure.micardis® (telmisartan) is an angiotensinreceptor blocker (arb) registeredfor the treatment of hypertension andthe reduction of cardiovascular morbidityand mortality. This was achieved asa result of a vast and robust body of research,including the ONTARGETstudy, one of the most ambitious andfar-reaching research programmes everconducted with an arb.Evolution of the global brandmicardis® was discovered and developedby Boehringer Ingelheim andwas launched in 1998. The product iscurrently registered in 112 countriesand marketed in 104 countries worldwide.It is the foundation for the telmisartanfranchise, which also includesmicar dis plus® and twynsta®.Organ protection and cardiovascularpreventionHistorically, the point of difference formicardis® was “full 24-hour bloodpressure protection”, which includedcover for the risky early morning hours,where other medicines can wear off. In2006, this shifted to its “powerful 24-hour blood pressure lowering effect”,which was felt to be more meaningfulby doctors.MICARDIS®For the treatment of hypertension.For the reduction of cardiovascularmorbidity in patients with manifestatherothrombotic cardiovasculardisease (history of coronary heartdisease, stroke or peripheral arterialdisease) or type 2 diabeteswith documented target organdamage.Controlling hypertension and cardiovascular protection73